Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

The Minister of Public Health Dr. Firass Abiad at COP28 in UAE

 
The Minister of Public Health (MoPH), Dr. Firass Abiad, will be participating in the COP28 held in UAE from November 30 to December 12, where leaders from around the world convene annually to address the dangerous human interference with the climate system. The Minister’s participation in COP28 UAE is particularly important as it would be the first COP with an explicit health focus. Dr. Abiad, the Minister of Public Health, Eng. Joyce Haddad, the Director of Preventive Healthcare at MoPH, Dr. Myriam Mrad, the Director of the Public Health Department at the University of Balamand and the Ministry Technical Collaborator will be representing the ministry of public health in the Lebanese national delegation.  

Minister Abiad will emphasize the imperative need to prioritize public health concerns in Lebanon within the broader discourse on climate change. Acknowledging the undeniable impact of environmental factors on human health, Dr. Abiad will commit to advocate for proactive measures and collaborative strategies to mitigate these effects in Lebanon.

The Minister will stress key initiatives aiming at safeguarding public health amidst environmental shifts, emphasizing the urgency of adaptation measures and the development of resilient healthcare systems. These initiatives align with the Lebanese Ministry of Public Health's commitment to promoting sustainable health practices and ensuring equitable access to healthcare for all citizens.

Additionally, Dr. Abiad will participate in high-level dialogues, fostering collaborations with global stakeholders and reaffirming Lebanon's dedication to the global fight against climate change, particularly in preserving public health.

It is worth noting that earlier this year, the MoPH endorsed COP26 proceedings in an official letter signed and dated March 26, 2023.  As part of this initiative, Lebanon committed to prioritizing the health needs of its population, while simultaneously addressing the environmental and sustainability challenges facing its healthcare facilities.

The MoPH remains steadfast in its commitment to integrating climate resilience into public health policies, aligning efforts with international agendas to safeguard the well-being of citizens and future generations.
    ...
    14
    ...
ATC Name B/G Ingredients Dosage Form Price
A10BG03 ACTOS B Pioglitazone HCl - 15mg 15mg Tablet 1,243,054 L.L
C09CA03 ARBITEN 160 G Valsartan - 160mg 160mg Tablet 544,256 L.L
G04BE08 APO-TADALAFIL G Tadalafil - 10mg 10mg Tablet 888,280 L.L
B01AF02 APO-APIXABAN G Apixaban - 5mg 5mg Tablet 3,084,119 L.L
J01CR02 AMOCLAN BID G Amoxicillin (trihydrate) - 400mg/5ml, Clavulanic Acid (potassium) - 57.1mg/5ml 457mg/57mg Tablet, chewable 892,311 L.L
C10AA05 ATORVASTATINE ARROW GENERIQUES G Atorvastatin - 80mg 80mg Tablet, coated 564,414 L.L
C10AA05 ATORVASTATINE ARROW GENERIQUES G Atorvastatin - 80mg 80mg Tablet, coated 564,414 L.L
C07AB04 ACEBUTOLOL BIOGARAN G Acebutolol HCl - 400mg 400mg Tablet, coated 615,480 L.L
C07AB04 ACEBUTOLOL BIOGARAN G Acebutolol HCl - 200mg 200mg Tablet, coated 464,970 L.L
M05BA06 ADROMUX G Ibandronic acid - 150mg 150mg Tablet, coated 821,088 L.L
C09DB01 AMLODIPINE/VALSARTAN ARROW G Amlodipine (besylate) - 5mg, Valsartan - 160mg Tablet, coated 923,220 L.L
C09DB01 AMLODIPINE/VALSARTAN ARROW G Amlodipine (besylate) - 10mg, Valsartan - 160mg Tablet, coated 923,220 L.L
C09DB01 AMLODIPINE/VALSARTAN ARROW G Amlodipine (besylate) - 5mg, Valsartan - 80mg Tablet, coated 807,649 L.L
A03E ACTICARBINE G Activated charcoal - 70mg, Papaverine HCl - 14mg Tablet, coated 311,771 L.L
L02BG03 ANASTROZOLE BIOGARAN G Anastrozole - 1mg 1mg Tablet, coated 3,800,387 L.L
R02A ALFA-AMYLASE BGR CONSEIL G Alpha-Amylase - 3,000U.CEIP 3,000U.CEIP Tablet, coated 290,270 L.L
C10AA05 ATORVASTATINE ARROW GENERIQUES G Atorvastatin - 10mg 10mg Tablet, coated 567,102 L.L
C10AA05 ATORVASTATINE ARROW GENERIQUES G Atorvastatin - 10mg 10mg Tablet, coated 567,102 L.L
C02AB02 ALDOMET B Methyldopa - 250mg 250mg Tablet, coated 619,853 L.L
C02AB02 ALDOMET B Methyldopa - 500mg 500mg Tablet, coated 824,074 L.L
C10AA05 ATORVASTATINE ARROW GENERIQUES G Atorvastatin - 20mg 20mg Tablet, coated 567,102 L.L
C10AA05 ATORVASTATINE ARROW GENERIQUES G Atorvastatin - 20mg 20mg Tablet, coated 567,102 L.L
C10AA05 ATORVASTATINE ARROW GENERQUES G Atorvastatin - 40mg 40mg Tablet, coated 564,414 L.L
C10AA05 ATORVASTATINE ARROW GENERQUES G Atorvastatin - 40mg 40mg Tablet, coated 564,414 L.L
G04CA01 ALFUZOSINE BIOGARAN LP G Alfuzosin HCl - 10mg 10mg Tablet, coated, prolonged release 1,115,389 L.L
J01CA04 AMOXICILLINE ARROW LAB G Amoxicillin (trihydrate) - 1g 1g Tablet, dispersible 940,690 L.L
R05CB01 ACC LONG G N-acetylcysteine - 600mg, Vitamin C - 75mg 600mg Tablet, effervescent 286,238 L.L
N02AJ06 ALGOCOD G Paracetamol - 500mg, Codeine phosphate - 30mg Tablet, effervescent 299,677 L.L
N02BA51 ASPIRINE C EFFERVESCENT B Acetylsalicylic acid - 400mg, Vitamin C - 240mg Tablet, effervescent 162,605 L.L
A07EC02 ASACOL B Mesalazine - 400mg 400mg Tablet, enteric coated 5,895,437 L.L
    ...
    14
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025